Join our community of smart investors

AstraZeneca bolstered by new drug sales

The group also benefited from £1.2bn in revenues from its Covid-19 vaccine
AstraZeneca bolstered by new drug sales
  • The FTSE 100 pharma giant has been rolling out its virus jab developed with Oxford university
  • But efforts to provide equitable access led to a drop in the gross margin
IC TIP: Buy

The launch of AstraZeneca’s (AZN) Covid-19 vaccine may not exactly have been smooth, with concerns mounting earlier this year about a very rare side effect of blood clotting. But the jab developed with Oxford university still contributed $1.2bn (£863m) to the FTSE 100 group’s revenues for the six months ending 30 June, benefiting its top line in Europe and emerging markets where the shot has been approved.

To continue reading...
Join our Community of Smart Investors
  • Independent full-length company analysis
  • Actionable investment ideas and recommendations
  • Expert investment tools and data
  • Stock screens from Algy Hall
Have an account? Sign in